Navitoclax | CAS No. 923564-51-6

Navitoclax

Basic Information

View in Editor

CAS Number

923564-51-6

Molecular Formula

C47H55ClF3N5O6S3

Molecular Weight

974.63 g/mol

Chemical Classification

Basic Chemical Raw Materials Organic Chemicals Carboxylic Acids

Basic Chemical Raw Materials Organic Chemicals Ethers

Basic Chemical Raw Materials Organic Chemicals Heterocyclic Compounds

Pharmaceutical Chemicals Pharmaceutical Intermediates Heterocyclic Intermediates

Fine Chemicals Dyes and Pigments Organic Dyes

Fine Chemicals Surfactants Anionic Surfactants

Fine Chemicals Specialty Chemicals UV Stabilizers

Agricultural Chemicals Pesticides Herbicides

Laboratory Chemicals Research Chemicals Biochemical Reagents

Basic Physical Properties

Melting Point

114-116°C

SMILES

View in Editor

CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C

InChI

InChI=1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1

InChIKey

JLYAXFNOILIKPP-KXQOOQHDSA-N

LogP

8.833200000000003

Topological Polar Surface Area

128.35999999999999 Å²

Hydrogen Bond Donor/Acceptor

2 / 11

Complexity

1800

Safety Information

View Safety Information

Hazard Statement

H302 Harmful if swallowed
Acute toxicity, oral

H315 Causes skin irritation
Skin corrosion/irritation

H319 Causes serious eye irritation
Serious eye damage/eye irritation

H335 May cause respiratory irritation
Specific target organ toxicity, single exposure; Respiratory tract irritation

Synonyms & References

English

ABT 263
4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide
Navitoclax
ABT-263
(R)-4-(4-((2-(4-Chlorophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(4-(4-morpholino-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)p
(S)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benza
ABT-263 (NAVITOCLAX)
Benzamide, 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[...
Navitoclax (ABT-263,ABT 263)
SLK-14-09-S1001
(R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide
ABT263
XKJ5VVK2WD
C47H55ClF3N5O6S3
4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide
4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl
4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide (ACI)
A 855071.0
Navitoclax(ABT-263)
EX-A055
ABT-263 In Bulk
Navitoclax; ABT-263
ABT-263,Navitoclax
GTPL8319
JLYAXFNOILIKPP-KXQOOQHDSA-N
J-519525
BRD-K82746043-001-19-3
CHEBI:131174
4-{4-[(4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro[biphenyl]-2-yl)methyl]piperazin-1-yl}-N-[(4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]benzamide
Navitoclax (ABT-263)
SCHEMBL522847

MDL Number

MFCD12756219

Customs Code

29339900

FAQ

What are the physical and chemical properties of Navitoclax (CAS: 923564-51-6)?

Navitoclax is a crystalline compound with a molecular weight of approximately 435.34 g/mol. It has a solubility of about 20 mg/mL in DMSO and is poorly soluble in water. Navitoclax is a potent inhibitor of BCL-2 family proteins, which makes it reactive towards these targets. It is stable under normal laboratory conditions but requires careful handling to maintain its activity.

How is Navitoclax (CAS: 923564-51-6) typically synthesized?

Navitoclax is typically synthesized through a multi-step organic synthesis route. The key steps involve the protection of the hydroxyl groups, formation of the amide bond, and subsequent deprotection. Common catalysts used include TBTU and HATU, and the synthetic method is highly selective, yielding around 80-85% purity. The process is optimized for efficiency and scalability.

What industries use Navitoclax (CAS: 923564-51-6)?

Navitoclax is primarily used in the pharmaceutical industry, particularly in cancer research and treatment. It has shown promise in clinical trials for the treatment of various hematological malignancies. Additionally, it has potential applications in the development of new drug candidates and as a tool compound in biological and chemical research.

What precautions should be taken when handling Navitoclax (CAS: 923564-51-6)?

When handling Navitoclax, it is essential to use appropriate personal protective equipment (PPE) such as gloves and a lab coat. Work should be conducted in a well-ventilated fume hood to minimize exposure. Spills should be cleaned up immediately with appropriate materials, and the Material Safety Data Sheet (MSDS) should be consulted for detailed safety information. Navitoclax is not a highly hazardous substance, but it should be handled with care to avoid skin contact and inhalation of dust.